An observational study in LGMD1B, LGMD1C and LGMD1D, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to participants aged 6 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Virginia Commonwealth University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Muscular Dystrophies with a site in United States — 32 open to participants now, 43 under way, 2 of them phase 3. Muscular Dystrophies · United States.
Among the 127 studies in Muscular Dystrophies with a site in United States, this one is the 8th largest by planned enrollment of the 44 observational ones that give a count, is one of 10 that started in 2023, is one of 45 observational ones, reaches primary completion later than 23 of the 41 other live ones, and was the 105th registered.
224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.
Browse Muscular Dystrophies studies →32 of the 127 studies in Muscular Dystrophies with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Virginia Commonwealth University · Sites in United States
Ages 18–70
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 5–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.
This study: 6 Years to 50 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 16 · Phase 4 2
First in 1978; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 111 across 74 observational studies indexed under Muscular Dystrophies.
Median enrollment 41 across the 80 interventional studies, 109 across the 44 observational. Of the 76 that completed or were terminated, 28 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 127 have an industry lead sponsor. The 10 most frequent:
Virginia Commonwealth University is the lead sponsor of 648 studies on the registry; 79 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 64 (71%) have results posted.
Virginia Commonwealth University has 4 studies filed under Muscular Dystrophies — fewer than ten, so there is no comparison to draw.
13 of the studies in Muscular Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT05854433Wake Forest University Health SciencesBrain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 | 2027-06 |
| NCT07502989Beth Israel Deaconess Medical CenterMuscle Health Measurements Using Electrical Impedance Myography | 2027-06-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 127 studies in Muscular Dystrophies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
Limb Girdle Muscular Dystrophy (LGMD) comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies.
Myotonic Dystrophy Type 2 (DM2) is a more recently discovered, rare type of myotonic dystrophy. DM2 is inherited in an autosomal dominant pattern and is caused by an unstable CCTG expansion. DM2 affects the muscles and other body systems (e.g. heart and eyes).
Pompe disease is a rare, multisystemic, hereditary disease which is caused by pathogenic variations in the GAA gene. Late onset Pompe disease (LOPD) refers to cases in which hypertrophic cardiomyopathy did not manifest or was not diagnosed at or under the age of 1 year. LOPD is characterized by skeletal muscle weakness which causes mobility problems and impacts the respiratory system.
The overall goal of this project is to extend prior observational studies conducted within the GRASP LGMD network to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for multiple rare types of muscular dystrophy to hasten therapeutic development.
The study seeks to enroll ambulatory individuals aged 6-50 years at enrollment who are clinically affected by LGMD, DM2, or LOPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To explore the suitability and feasibility of the North Star Assessment for LGMD (NSAD) in the muscular dystrophies
The NSAD is a functional scale specifically designed to measure motor performance in individuals with LGMD. It consists of 29 items that are considered clinically relevant items from the adapted North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54.
Time frame: Baseline to 24 months
To explore the utility of the 100 meter timed test as a clinical outcome assessment in the muscular dystrophies
The participant will be asked to complete 4 laps around 2 cones set 25 meters apart, as quickly and safely as possible, walking or running if able. The total time to complete the 4 laps is recorded in seconds.
Time frame: Baseline to 24 months
To explore the utility of the Performance of the Upper Limb 2.0 (PUL 2.0) assessment as a clinical outcome assessment in the muscular dystrophies
The PUL 2.0 is a tool designed for assessing upper limb function in persons with neuromuscular disorders. It was developed as a conceptual framework reflecting the progression of weakness and natural history of functional decline in Duchenne Muscular Dystrophy (DMD). There are 22 scored items; a score of 42 indicates the highest level of independent function and 0 the lowest.
Time frame: Baseline to 24 months
To explore the utility of spirometry as a clinical outcome assessment in the muscular dystrophies
Spirometry is a breathing assessment comprised of: seated and supine forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and slow vital capacity (SVC). This assessment is performed using standardized equipment.
Time frame: Baseline to 24 months
To explore the utility of the LGMD-HI questionnaire as a patient-reported outcome measure in the muscular dystrophies.
The LGMD Health Index (LGMD-HI) is a disease-specific, patient-reported measure that assesses overall health-related quality of life in LGMD.
Time frame: Baseline to 24 months
To explore the utility of the PROMIS-57 as a patient-reported outcome measure in the muscular dystrophies.
The PROMIS-57 is a set of patient-reported measures developed by the NIH. The social health set of questions evaluates general social health by assessing ability to participate in social roles and activities, companionship, satisfaction with social roles and activities, social isolation, and social support. The mental health set evaluates general mental health by assessing anxiety, depression, alcohol use, anger, cognitive function, life satisfaction, meaning and purpose, positive affect, psychosocial illness impact, self-efficacy for managing chronic conditions, smoking, and substance use. The physical health set evaluates general physical health by assessing fatigue, pain intensity, pain interference, physical function, sleep disturbance, dyspnea, gastrointestinal symptoms, itch, pain behavior, pain quality, sexual function, and sleep related impairment.
Time frame: Baseline to 24 months
To explore the utility of the Domain Delta as a patient-reported outcome measure in the muscular dystrophies
The Domain Delta questionnaire is a patient-reported outcome measure that assesses overall health over the previous 12 months.
Time frame: Baseline to 24 months
Plan to share: No — Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the LGMD investigators.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2028, 59 months after the start.
Of 37 observational studies under Muscular Dystrophies, half reached primary completion within 113 months of starting (the median), counting those still running; a quarter within 38. This study's planned 59 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Virginia Commonwealth University →